Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents
Objectives: To assess the long-term (3 years) safety and efficacy of Tetrilimus everolimus-eluting stent (EES) and subgroup analysis of outcomes of ultra-long (44/48 mm) Tetrilimus EES implantation in patients with long coronary lesions. Material and methods: In this observational, single-centre, si...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Indian Heart Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0019483223000469 |
| _version_ | 1797755853516832768 |
|---|---|
| author | Raghava Sarma Polavarapu Vijaya Pamidimukkala Anurag Polavarapu Yudhistar Siripuram Keerthika Chowdary Ravella Murali Babu Rao Rachaputi Naren Polavarapu Kalyan Chakravarthi Pulivarthi Sravanthi Byrapaneni Sirichandana Gangasani Michael Noronha Srinivasa Rao Chinta |
| author_facet | Raghava Sarma Polavarapu Vijaya Pamidimukkala Anurag Polavarapu Yudhistar Siripuram Keerthika Chowdary Ravella Murali Babu Rao Rachaputi Naren Polavarapu Kalyan Chakravarthi Pulivarthi Sravanthi Byrapaneni Sirichandana Gangasani Michael Noronha Srinivasa Rao Chinta |
| author_sort | Raghava Sarma Polavarapu |
| collection | DOAJ |
| description | Objectives: To assess the long-term (3 years) safety and efficacy of Tetrilimus everolimus-eluting stent (EES) and subgroup analysis of outcomes of ultra-long (44/48 mm) Tetrilimus EES implantation in patients with long coronary lesions. Material and methods: In this observational, single-centre, single-arm, investigator-initiated registry, 558 patients who underwent implantation of Tetrilimus EES for the treatment of coronary artery disease were retrospectively included. The primary endpoint was occurrence of any major adverse cardiac event (MACE) at 12 months follow-up (composite of cardiac death, myocardial infarction [MI], and target lesion revascularization [TLR]) and we hereby report 3 years follow-up data. Stent thrombosis was assessed as a safety endpoint. A subgroup analysis of patients with long coronary lesions is also reported. Results: A total of 558 patients (57.0 ± 10.2 years) received 766 Tetrilimus EES (1.3 ± 0.5 stents/patient) to treat 695 coronary lesions. In subgroup analysis of 143 patients implanted with ultra-long EES, 155 lesions were intervened successfully with only one Tetrilimus EES (44/48 mm) implanted per lesion. At 3 years, event rates of 9.1% MACE with predominance of MI (4.4%), followed by 2.9% TLR and 1.7% cardiac death, and only 1.0% stent thrombosis were reported in overall population, while in a subgroup of patients implanted with ultra-long EES, 10.4% MACE and 1.5% stent thrombosis were reported. Conclusions: Three years clinical outcomes showed favourable long-term safety and excellent performance of Tetrilimus EES in high-risk patients and complex coronary lesions in routine clinical practice, including a subgroup of patients with long coronary lesions, with acceptable primary and safety endpoints. |
| first_indexed | 2024-03-12T17:53:06Z |
| format | Article |
| id | doaj.art-f53fcdc746e7484ab11f634987f71bb3 |
| institution | Directory Open Access Journal |
| issn | 0019-4832 |
| language | English |
| last_indexed | 2024-03-12T17:53:06Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Indian Heart Journal |
| spelling | doaj.art-f53fcdc746e7484ab11f634987f71bb32023-08-03T04:22:24ZengElsevierIndian Heart Journal0019-48322023-07-01754279284Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stentsRaghava Sarma Polavarapu0Vijaya Pamidimukkala1Anurag Polavarapu2Yudhistar Siripuram3Keerthika Chowdary Ravella4Murali Babu Rao Rachaputi5Naren Polavarapu6Kalyan Chakravarthi Pulivarthi7Sravanthi Byrapaneni8Sirichandana Gangasani9Michael Noronha10Srinivasa Rao Chinta11Department of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, India; Corresponding author. Department of Cardiology, Lalitha Super Specialties Hospital, Kothapet Main Rd, Kothapeta, Guntur, Andhra Pradesh, 522001, India.Department of Neurosciences, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of General Medicine, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Oncology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of General Medicine, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaDepartment of Cardiology, Lalitha Super Specialities Hospital, Guntur, Andhra Pradesh, IndiaObjectives: To assess the long-term (3 years) safety and efficacy of Tetrilimus everolimus-eluting stent (EES) and subgroup analysis of outcomes of ultra-long (44/48 mm) Tetrilimus EES implantation in patients with long coronary lesions. Material and methods: In this observational, single-centre, single-arm, investigator-initiated registry, 558 patients who underwent implantation of Tetrilimus EES for the treatment of coronary artery disease were retrospectively included. The primary endpoint was occurrence of any major adverse cardiac event (MACE) at 12 months follow-up (composite of cardiac death, myocardial infarction [MI], and target lesion revascularization [TLR]) and we hereby report 3 years follow-up data. Stent thrombosis was assessed as a safety endpoint. A subgroup analysis of patients with long coronary lesions is also reported. Results: A total of 558 patients (57.0 ± 10.2 years) received 766 Tetrilimus EES (1.3 ± 0.5 stents/patient) to treat 695 coronary lesions. In subgroup analysis of 143 patients implanted with ultra-long EES, 155 lesions were intervened successfully with only one Tetrilimus EES (44/48 mm) implanted per lesion. At 3 years, event rates of 9.1% MACE with predominance of MI (4.4%), followed by 2.9% TLR and 1.7% cardiac death, and only 1.0% stent thrombosis were reported in overall population, while in a subgroup of patients implanted with ultra-long EES, 10.4% MACE and 1.5% stent thrombosis were reported. Conclusions: Three years clinical outcomes showed favourable long-term safety and excellent performance of Tetrilimus EES in high-risk patients and complex coronary lesions in routine clinical practice, including a subgroup of patients with long coronary lesions, with acceptable primary and safety endpoints.http://www.sciencedirect.com/science/article/pii/S0019483223000469Biodegradable polymerDrug-eluting stentsEverolimusPercutaneous coronary intervention |
| spellingShingle | Raghava Sarma Polavarapu Vijaya Pamidimukkala Anurag Polavarapu Yudhistar Siripuram Keerthika Chowdary Ravella Murali Babu Rao Rachaputi Naren Polavarapu Kalyan Chakravarthi Pulivarthi Sravanthi Byrapaneni Sirichandana Gangasani Michael Noronha Srinivasa Rao Chinta Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents Indian Heart Journal Biodegradable polymer Drug-eluting stents Everolimus Percutaneous coronary intervention |
| title | Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents |
| title_full | Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents |
| title_fullStr | Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents |
| title_full_unstemmed | Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents |
| title_short | Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents |
| title_sort | ultra thin everolimus eluting stents in atherosclerotic lesions three years follow up with subgroup analysis of ultra long stents |
| topic | Biodegradable polymer Drug-eluting stents Everolimus Percutaneous coronary intervention |
| url | http://www.sciencedirect.com/science/article/pii/S0019483223000469 |
| work_keys_str_mv | AT raghavasarmapolavarapu ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT vijayapamidimukkala ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT anuragpolavarapu ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT yudhistarsiripuram ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT keerthikachowdaryravella ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT muralibaburaorachaputi ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT narenpolavarapu ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT kalyanchakravarthipulivarthi ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT sravanthibyrapaneni ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT sirichandanagangasani ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT michaelnoronha ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents AT srinivasaraochinta ultrathineverolimuselutingstentsinatheroscleroticlesionsthreeyearsfollowupwithsubgroupanalysisofultralongstents |